[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypogonadotropic-hypogonadism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypogonadotropic-hypogonadism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,67,79,92,124,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053509","phase-2-kisspeptin-administration-subcutaneously-to-patients-with-hypothalamic-amenorrhea-100053509",false,"NCT07224438","Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea","Inclusion Criteria:\n\n* Female\n* Ages 18-45 years\n* Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* Hemoglobin no less than 0.5 g\u002FdL below the lower limit of the reference range for normal women\n* Negative serum hCG pregnancy test\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis OR willing to complete an appropriate washout for that particular medication and its method of administration\n* If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug\n\nExclusion Criteria:\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding","FEMALE","18 Years","45 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.",[26,27],"Hypothalamic Amenorrhea","Hypogonadotropic Hypogonadism",[29,30,31],"hypothalamic amenorrhea","hypogonadotropic hypogonadism","kisspeptin","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-12-09",{"date":40,"type":20},"2030-05",{"name":42,"class":43},"Stephanie B. Seminara, MD","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100053862","phase-2-kisspeptin-administration-subcutaneously-to-patients-with-ihh-100053862","NCT05896293","Kisspeptin Administration Subcutaneously to Patients With IHH","Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders","Inclusion Criteria:\n\n* Congenital IHH\n* Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration\n* If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug\n\nExclusion Criteria:\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs (not including marijuana)\n* For women:\n* Pregnant or trying to become pregnant\n* Breast feeding\n* History of: bilateral oophorectomy (both ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding","ALL",{"count":54,"type":20},36,[23],"The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time.\n\nFunding Source: FDA OOPD",[27],[27,59,60],"Kisspeptin","Idiopathic Hypogonadotropic Hypogonadism",{"date":35,"type":36},{"date":63,"type":36},"2023-02-03",{"date":65,"type":20},"2028-05",{"name":42,"class":43},{"id":68,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":24,"conditions":71,"keywords":72,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":78,"locationsCount":44},"100610196",{"count":19,"type":20},[23],[26,27],[29,30,31],"2025-12-29",{"date":75,"type":36},"2025-12-31",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},{"id":80,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":56,"conditions":84,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":44},"100508122","Inclusion Criteria:\n\n* Congenital IHH\n\n  o Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration\n\nExclusion Criteria:\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek) and\u002For active use of illicit drugs\n\n  o Any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation.\n* Pregnant or trying to become pregnant\n* Breast feeding\n* History of: bilateral oophorectomy (both ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding",{"count":54,"type":20},[23],[27],[27,59,60],"2025-09-30",{"date":88,"type":36},"2025-10-03",{"date":63,"type":36},{"date":65,"type":20},{"name":42,"class":43},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":103,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":44},"100543559","assessment-of-endometrial-thickness-among-adolescent-and-young-adult-patients-on-estrogen-replacement-therapy-using-daily-oral-micronized-progesterone-versus-the-etonogestrel-implant-100543559","NCT06357442","Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.","Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Continuous Oral Micronized Progesterone Versus the Etonogestrel Implant: a Prospective Pilot Study","Inclusion Criteria:\n\n* Age 12-25 years at baseline\n* Female assigned at birth, with uterus\n* Diagnosis of primary ovarian insufficiency or hypogonadotropic hypogonadism, requiring estrogen replacement therapy\n* Receiving estradiol therapy-oral (1-2mg) or transdermal (0.05-0.1mg)-for at least 3 months\n* Never used progesterone therapy or discontinued progesterone therapy at least 90-days prior to enrollment\n* Consents to initiating progesterone therapy\n\nExclusion Criteria:\n\n* Uterine abnormality (e.g., Müllerian Anomaly, uterine fibroids)\n* Inability to characterize the endometrial lining on ultrasound\n* History of chemotherapy or radiation therapy\n* Inability to complete study questionnaire","12 Years","25 Years",{"count":102,"type":20},34,"6 Months","OBSERVATIONAL","The goal of this observational study is to compare endometrial stripe thickness in adolescent and young adult (AYA) patients with a uterus on estrogen replacement therapy using oral progesterone versus the etonogstrel implant for endometrial protection.\n\nThe main questions it aims to answer are:\n\nAim 1: Characterize the mean endometrial thickness in AYA on estrogen hormone replacement therapy before initiation of progesterone therapy\n\nAim 2: Characterize the mean changes and variability in endometrial thickness in AYA treated for 6 months with either the etonogestrel implant or continuous oral progesterone\n\nAim 3: Assess satisfaction, side effects, bleeding patterns, any progesterone modifications, and adherence in AYA treated for 6 months with either etonogestrel implant or continuous progesterone\n\nParticipants will be asked to:\n\n* Get two pelvic ultrasounds\n* Fill out two surveys\n* Continue their current hormone replacement therapy\n* Initiate one of two progesterone therapies (prometrium 100mg daily or Nexplanon)\n\nResearchers will compare the change in endometrial thickness after 6 months of progesterone use to see if there is a significant difference in the mean change between the prometrium and Nexplanon groups.",[107,27,108],"Primary Ovarian Insufficiency","Hormone Replacement Therapy",[110,111,112,113,114],"hormone replacement therapy","hypogonadism","primary ovarian insufficiency","endometrial protection","progesterone replacement therapy","2024-12-03",{"date":117,"type":36},"2024-12-06",{"date":119,"type":36},"2024-07-01",{"date":121,"type":20},"2026-07-01",{"name":123,"class":43},"University of Colorado, Denver",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":52,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":139,"conditions":140,"keywords":149,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":5},"100381852","growing-up-with-the-young-endocrine-support-system-yess-100381852","NCT04252001","Growing up With the Young Endocrine Support System (YESS!)","Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care","YESS","Inclusion Criteria:\n\n* Aged 15 to 20 years old.\n* Diagnosed with congenital adrenal hyperplasia, hypogonadotropic hypogonadism, Turner syndrome, Klinefelter syndrome, growth hormone deficiency, combined pituitary hormone deficiency, Androgen insensitivity syndrome, thyroid dysgenesis or Addison's disease\n\nExclusion Criteria:\n\n* Lack of a mobile phone or tablet.\n* Intellectual disability or language barrier leading to inability to use the YESS! game or the control game.",true,"15 Years","20 Years",{"count":136,"type":20},160,[138],"NA","Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game.",[141,27,142,143,144,145,146,147,148],"Congenital Adrenal Hyperplasia","Growth Hormone Deficiency","Combined Pituitary Hormone Deficiency","Turner Syndrome","Klinefelter Syndrome","Addison's Disease","Androgen Insensitivity Syndrome","Thyroid Dysgenesis",[150,151,152],"Serious game","Endocrinology","Transition","NOT_YET_RECRUITING","2023-09-06",{"date":156,"type":36},"2023-09-07",{"date":158,"type":20},"2024-12-01",{"date":160,"type":20},"2026-12-01",{"name":162,"class":43},"dr. Laura C. G. de Graaff-Herder",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":132,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":172,"conditions":173,"keywords":180,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":44},"100178744","genetics-of-reproductive-disorders-including-kallmann-syndrome-and-cleft-lip-andor-palate-100178744","NCT01601171","Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and\u002For Palate","The Genetics of Neuroendocrine Reproductive Disorders and of the Cleft Lip and\u002For Palate","Inclusion Criteria:(any of the following conditions)\n\n* hypogonadotropic hypogonadism\n* Kallmann syndrome\n* adult-onset hypogonadotropic hypogonadism\n* hypothalamic amenorrhea\n* polycystic ovarian syndrome\n* primary gonadal failure\n* precocious puberty\n* cleft lip\u002Fpalate\n* family members of the above groups\n\nExclusion Criteria:\n\n* acute illness\u002Fhospitalization\n* pituitary tumors\n* iron overload (hemochromatosis)\n* infiltrative diseases (sarcoidosis)\n* chronic alcohol abuse\n* illicit drug use\n* anabolic steroid abuse",{"count":171,"type":20},2000,"The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and\u002For palate.",[174,27,26,175,176,177,178,179],"Kallmann Syndrome","Polycystic Ovarian Syndrome","Precocious Puberty","Cleft Lip and Palate","Cleft Palate","Cleft Lip",[181,111,182,183,184,185,186,187],"GnRH deficiency","anosmia","infertility","cleft lip","cleft palate","cryptorchidism","microphallus","2022-06-17",{"date":190,"type":36},"2022-06-21",{"date":192,"type":4},"2012-03",{"date":194,"type":20},"2030-03",{"name":196,"class":43},"Centre Hospitalier Universitaire Vaudois"]